Groner Targeted Interference with Signal Transduction Events

2007
ISBN: 978-3-540-31209-3
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 188 Seiten, eBook

Reihe: Medicine (R0)

This book does nothing less than lay out the state of development of tomorrow’s cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities. The sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to derive more efficient cancer drugs?

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Groner, B.

Inhaltsverzeichnis

Introduction: The Rationale for the Development of Targeted Drugs in Cancer Therapy.- Identifying Critical Signaling Molecules for the Treatment of Cancer.- Tyrosine Kinase Inhibitors and Cancer Therapy.- Targeting ERBB Receptors in Cancer.- Inhibition of the IGF-I Receptor for Treatment of Cancer. Kinase Inhibitors and Monoclonal Antibodies as Alternative Approaches.- Inhibition of the TGF-? Signaling Pathway in Tumor Cells.- The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition.- The Ras Signalling Pathway as a Target in Cancer Therapy.- The Mitogen-Activated Protein Kinase Pathway for Molecular-Targeted Cancer Treatment.- Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Events.